A citation-based method for searching scientific literature

Tomonari Kimura, Kazufumi Nakamura, Toru Miyoshi, Masashi Yoshida, Kaoru Akazawa, Yukihiro Saito, Satoshi Akagi, Yuko Ohno, Megumi Kondo, Daiji Miura, Jun Wada, Hiroshi Ito. Int Heart J 2019
Times Cited: 4







List of co-cited articles
8 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
50

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
967
50

Effect of Luseogliflozin on Heart Failure With Preserved Ejection Fraction in Patients With Diabetes Mellitus.
Kentaro Ejiri, Toru Miyoshi, Hajime Kihara, Yoshiki Hata, Toshihiko Nagano, Atsushi Takaishi, Hironobu Toda, Seiji Nanba, Yoichi Nakamura, Satoshi Akagi,[...]. J Am Heart Assoc 2020
5
50

Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes.
R Chilton, I Tikkanen, C P Cannon, S Crowe, H J Woerle, U C Broedl, O E Johansen. Diabetes Obes Metab 2015
217
50

Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial.
Stefan D Anker, Javed Butler, Gerasimos S Filippatos, Waheed Jamal, Afshin Salsali, Janet Schnee, Karen Kimura, Cordula Zeller, Jyothis George, Martina Brueckmann,[...]. Eur J Heart Fail 2019
66
50

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
50

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
50

Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.
David Z I Cherney, Bruce A Perkins, Nima Soleymanlou, Maria Maione, Vesta Lai, Alana Lee, Nora M Fagan, Hans J Woerle, Odd Erik Johansen, Uli C Broedl,[...]. Circulation 2014
650
50

The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus.
David Zi Cherney, Bruce A Perkins, Nima Soleymanlou, Ronnie Har, Nora Fagan, Odd Erik Johansen, Hans-Juergen Woerle, Maximilian von Eynatten, Uli C Broedl. Cardiovasc Diabetol 2014
269
25

Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction.
Margaret M Redfield, Kevin J Anstrom, James A Levine, Gabe A Koepp, Barry A Borlaug, Horng H Chen, Martin M LeWinter, Susan M Joseph, Sanjiv J Shah, Marc J Semigran,[...]. N Engl J Med 2015
249
25

Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy.
Michel F Rousseau, Olivier Gurné, Daniel Duprez, Walter Van Mieghem, Annie Robert, Sylvie Ahn, Laurence Galanti, Jean Marie Ketelslegers. J Am Coll Cardiol 2002
124
25

The perindopril in elderly people with chronic heart failure (PEP-CHF) study.
John G F Cleland, Michal Tendera, Jerzy Adamus, Nick Freemantle, Lech Polonski, Jacqueline Taylor. Eur Heart J 2006
780
25

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. Reply.
John J V McMurray, Kieran F Docherty, Pardeep S Jhund. N Engl J Med 2020
10
25

Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
Eri T Kato, Michael G Silverman, Ofri Mosenzon, Thomas A Zelniker, Avivit Cahn, Remo H M Furtado, Julia Kuder, Sabina A Murphy, Deepak L Bhatt, Lawrence A Leiter,[...]. Circulation 2019
166
25

Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure.
T Tsutamoto, A Wada, K Maeda, N Mabuchi, M Hayashi, T Tsutsui, M Ohnishi, M Sawaki, M Fujii, T Matsumoto,[...]. J Am Coll Cardiol 2001
227
25

The effect of luseogliflozin and alpha-glucosidase inhibitor on heart failure with preserved ejection fraction in diabetic patients: rationale and design of the MUSCAT-HF randomised controlled trial.
Kentaro Ejiri, Toru Miyoshi, Kazufumi Nakamura, Satoru Sakuragi, Mitsuru Munemasa, Seiji Namba, Atsushi Takaishi, Hiroshi Ito. BMJ Open 2019
1
100

Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial.
Salim Yusuf, Marc A Pfeffer, Karl Swedberg, Christopher B Granger, Peter Held, John J V McMurray, Eric L Michelson, Bertil Olofsson, Jan Ostergren. Lancet 2003
25

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.
Piotr Ponikowski, Adriaan A Voors, Stefan D Anker, Héctor Bueno, John G F Cleland, Andrew J S Coats, Volkmar Falk, José Ramón González-Juanatey, Veli-Pekka Harjola, Ewa A Jankowska,[...]. Eur Heart J 2016
25

Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction.
Remo H M Furtado, Marc P Bonaca, Itamar Raz, Thomas A Zelniker, Ofri Mosenzon, Avivit Cahn, Julia Kuder, Sabina A Murphy, Deepak L Bhatt, Lawrence A Leiter,[...]. Circulation 2019
90
25

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado,[...]. Lancet 2019
796
25


2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.
Clyde W Yancy, Mariell Jessup, Biykem Bozkurt, Javed Butler, Donald E Casey, Mark H Drazner, Gregg C Fonarow, Stephen A Geraci, Tamara Horwich, James L Januzzi,[...]. Circulation 2013
25


ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC.
John J V McMurray, Stamatis Adamopoulos, Stefan D Anker, Angelo Auricchio, Michael Böhm, Kenneth Dickstein, Volkmar Falk, Gerasimos Filippatos, Cândida Fonseca, Miguel Angel Gomez-Sanchez,[...]. Eur Heart J 2012
25

Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.
Jean-Louis Chiasson, Robert G Josse, Ramon Gomis, Markolf Hanefeld, Avraham Karasik, Markku Laakso. JAMA 2003
25

Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials.
John G F Cleland, Karina V Bunting, Marcus D Flather, Douglas G Altman, Jane Holmes, Andrew J S Coats, Luis Manzano, John J V McMurray, Frank Ruschitzka, Dirk J van Veldhuisen,[...]. Eur Heart J 2018
165
25

Spironolactone for heart failure with preserved ejection fraction.
Bertram Pitt, Marc A Pfeffer, Susan F Assmann, Robin Boineau, Inder S Anand, Brian Claggett, Nadine Clausell, Akshay S Desai, Rafael Diaz, Jerome L Fleg,[...]. N Engl J Med 2014
25

Irbesartan in patients with heart failure and preserved ejection fraction.
Barry M Massie, Peter E Carson, John J McMurray, Michel Komajda, Robert McKelvie, Michael R Zile, Susan Anderson, Mark Donovan, Erik Iverson, Christoph Staiger,[...]. N Engl J Med 2008
25

The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.
Scott D Solomon, Michael Zile, Burkert Pieske, Adriaan Voors, Amil Shah, Elisabeth Kraigher-Krainer, Victor Shi, Toni Bransford, Madoka Takeuchi, Jianjian Gong,[...]. Lancet 2012
615
25


Omega-3 fatty acids improve postprandial lipemia and associated endothelial dysfunction in healthy individuals - a randomized cross-over trial.
Toru Miyoshi, Yoko Noda, Yuko Ohno, Hiroki Sugiyama, Hiroki Oe, Kazufumi Nakamura, Kunihisa Kohno, Hiroshi Ito. Biomed Pharmacother 2014
29
25

Serum triglycerides and risk of coronary heart disease among Japanese men and women.
H Iso, Y Naito, S Sato, A Kitamura, T Okamura, T Sankai, T Shimamoto, M Iida, Y Komachi. Am J Epidemiol 2001
202
25

Sex Differences in Renal Inflammation and Injury in High-Fat Diet-Fed Dahl Salt-Sensitive Rats.
Roxanne Fernandes, Hannah Garver, Jack R Harkema, James J Galligan, Gregory D Fink, Hui Xu. Hypertension 2018
16
25

Postprandial hyperlipidemia as a potential residual risk factor.
Kazufumi Nakamura, Toru Miyoshi, Kei Yunoki, Hiroshi Ito. J Cardiol 2016
47
25

Effects of pemafibrate (K-877) on cholesterol efflux capacity and postprandial hyperlipidemia in patients with atherogenic dyslipidemia.
Shizuya Yamashita, Hidenori Arai, Koutaro Yokote, Eiichi Araki, Hideki Suganami, Shun Ishibashi. J Clin Lipidol 2018
20
25

Remnant-like particles from subjects who died of coronary artery disease suppress NO synthase activity and attenuate endothelium-dependent vasorelaxation.
Naoki Ohara, Sanae Takeichi, Yukiko Naito, Yasuhiro Nakajima, Nobuhiro Yukawa, Takamitsu Nakano, Katsuyuki Nakajima. Clin Chim Acta 2003
12
25

Hypertension in mice lacking the gene for endothelial nitric oxide synthase.
P L Huang, Z Huang, H Mashimo, K D Bloch, M A Moskowitz, J A Bevan, M C Fishman. Nature 1995
25


Postprandial hypertriglyceridemia impairs endothelial function by enhanced oxidant stress.
J H Bae, E Bassenge, K B Kim, Y N Kim, K S Kim, H J Lee, K C Moon, M S Lee, K Y Park, M Schwemmer. Atherosclerosis 2001
222
25

Physiological Diagnostic Criteria for Vascular Failure.
Atsushi Tanaka, Hirofumi Tomiyama, Tatsuya Maruhashi, Yasushi Matsuzawa, Toru Miyoshi, Tomoyuki Kabutoya, Kazuomi Kario, Seigo Sugiyama, Masanori Munakata, Hiroshi Ito,[...]. Hypertension 2018
47
25

Pitavastatin inhibits upregulation of intermediate conductance calcium-activated potassium channels and coronary arteriolar remodeling induced by long-term blockade of nitric oxide synthesis.
Yutaka Terata, Takashi Saito, Yoshimasa Fujiwara, Hitoshi Hasegawa, Hiroto Miura, Hiroyuki Watanabe, Yoshikatsu Chiba, Satoshi Kibira, Mamoru Miura. Pharmacology 2003
14
25

A Novel Selective PPARα Modulator (SPPARMα), K-877 (Pemafibrate), Attenuates Postprandial Hypertriglyceridemia in Mice.
Masami Sairyo, Takuya Kobayashi, Daisaku Masuda, Koutaro Kanno, Yinghong Zhu, Takeshi Okada, Masahiro Koseki, Tohru Ohama, Makoto Nishida, Yasushi Sakata,[...]. J Atheroscler Thromb 2018
4
25

Pitavastatin improves cardiac function and survival in association with suppression of the myocardial endothelin system in a rat model of hypertensive heart failure.
Masako Saka, Koji Obata, Sahoko Ichihara, Xian Wu Cheng, Hirotaka Kimata, Takao Nishizawa, Akiko Noda, Hideo Izawa, Kohzo Nagata, Toyoaki Murohara,[...]. J Cardiovasc Pharmacol 2006
40
25

Bezafibrate improves postprandial hypertriglyceridemia and associated endothelial dysfunction in patients with metabolic syndrome: a randomized crossover study.
Yuko Ohno, Toru Miyoshi, Yoko Noda, Hiroki Oe, Norihisa Toh, Kazufumi Nakamura, Kunihisa Kohno, Hiroshi Morita, Hiroshi Ito. Cardiovasc Diabetol 2014
15
25

Post-prandial endothelial dysfunction in hypertriglyceridemic subjects: molecular mechanisms and gene expression studies.
Giuseppe Danilo Norata, Liliana Grigore, Sara Raselli, Laura Redaelli, Anders Hamsten, Franco Maggi, Per Eriksson, Alberico Luigi Catapano. Atherosclerosis 2007
83
25

Ezetimibe improves postprandial hyperlipemia and its induced endothelial dysfunction.
Kei Yunoki, Kazufumi Nakamura, Toru Miyoshi, Kenki Enko, Kunihisa Kohno, Hiroshi Morita, Kengo F Kusano, Hiroshi Ito. Atherosclerosis 2011
42
25

Postprandial recruitment of neutrophils may contribute to endothelial dysfunction.
A J H H M van Oostrom, T P Sijmonsma, C Verseyden, E H J M Jansen, E J P de Koning, T J Rabelink, M Castro Cabezas. J Lipid Res 2003
162
25


Effect of high fat loading in Dahl salt-sensitive rats.
Ai Nagae, Megumi Fujita, Hiroo Kawarazaki, Hiromitu Matsui, Katsuyuki Ando, Toshiro Fujita. Clin Exp Hypertens 2009
29
25

Impact of hypertriglyceridemia on endothelial dysfunction during statin ± ezetimibe therapy in patients with coronary heart disease.
Kei Yunoki, Kazufumi Nakamura, Toru Miyoshi, Kenki Enko, Motoki Kubo, Masato Murakami, Yoshiki Hata, Kunihisa Kohno, Hiroshi Morita, Kengo F Kusano,[...]. Am J Cardiol 2011
21
25


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.